BC Extra | Dec 7, 2019
Financial News

Jasper debuts with $35M series A, licenses antibody from Amgen to prep patients for transplants

With an antibody in-licensed from Amgen and a $35 million series A led by Abingworth and Qiming Venture Partners, Jasper is aiming to make stem cell transplants safer for patients. Surveyor Capital and Alexandria Venture...
BC Extra | Aug 14, 2019
Financial News

Aug. 14 Financial Quick Takes: Biotech tumbles with markets; plus Frontier, Portola and more

Biotech fares better than markets in sell-off  U.S. biotech indexes fared slightly better than the broader markets Wednesday as stocks tumbled amid fresh signs of a global economic slowdown and a signal from bond markets...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BC Extra | Apr 26, 2019
Company News

European regulatory roundup: CHMP opinions and a Portola approval

EMA's CHMP recommended a basket of approvals, including Dovato dolutegravir/lamivudine, Libtayo cemiplimab and two orphan therapies. Also Friday, the European Commission granted conditional approval to Ondexxya andexanet alfa from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) to reverse...
BC Extra | Apr 24, 2019
Company News

Management tracks: Portola, Assembly, Entasis

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said John Curnutte will retire as EVP and head of R&D on May 17 after eight years at the hematology company. SVP of Research Pamela Conley will lead research activities, effective...
BC Extra | Apr 11, 2019
Politics & Policy

Regulatory reprieve with Brexit delay

An EU-granted extension for Brexit means short-term clarity for biopharma companies expecting EMA or European Commission decisions before the new Oct. 31 deadline. The U.K. had been scheduled to leave the union Friday. At least...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BC Week In Review | Mar 8, 2019
Company News

CHMP recommendations include Ondexxya, Waylivra

EMA's CHMP recommended a basket of approvals and label extensions on March 1, including Ondexxya andexanet alfa and Waylivra volanesorsen. The agency recommended conditional approval of Ondexxya from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) as the first...
BC Extra | Mar 1, 2019
Company News

CHMP recommendations include Ondexxya, Waylivra

EMA's CHMP recommended a basket of approvals and label extensions Friday, including Ondexxya andexanet alfa and Waylivra volanesorsen. The agency recommended conditional approval of Ondexxya from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) as the first approved antidote...
BC Extra | Jan 28, 2019
Company News

Management tracks: Ironwood reveals board for new companies

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) named Mark Currie as incoming president of its spinout Cyclerion Therapeutics Inc. Currie will also join Ironwood's board following the separation, which is on track to occur this half. He is...
Items per page:
1 - 10 of 270
BC Extra | Dec 7, 2019
Financial News

Jasper debuts with $35M series A, licenses antibody from Amgen to prep patients for transplants

With an antibody in-licensed from Amgen and a $35 million series A led by Abingworth and Qiming Venture Partners, Jasper is aiming to make stem cell transplants safer for patients. Surveyor Capital and Alexandria Venture...
BC Extra | Aug 14, 2019
Financial News

Aug. 14 Financial Quick Takes: Biotech tumbles with markets; plus Frontier, Portola and more

Biotech fares better than markets in sell-off  U.S. biotech indexes fared slightly better than the broader markets Wednesday as stocks tumbled amid fresh signs of a global economic slowdown and a signal from bond markets...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BC Extra | Apr 26, 2019
Company News

European regulatory roundup: CHMP opinions and a Portola approval

EMA's CHMP recommended a basket of approvals, including Dovato dolutegravir/lamivudine, Libtayo cemiplimab and two orphan therapies. Also Friday, the European Commission granted conditional approval to Ondexxya andexanet alfa from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) to reverse...
BC Extra | Apr 24, 2019
Company News

Management tracks: Portola, Assembly, Entasis

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said John Curnutte will retire as EVP and head of R&D on May 17 after eight years at the hematology company. SVP of Research Pamela Conley will lead research activities, effective...
BC Extra | Apr 11, 2019
Politics & Policy

Regulatory reprieve with Brexit delay

An EU-granted extension for Brexit means short-term clarity for biopharma companies expecting EMA or European Commission decisions before the new Oct. 31 deadline. The U.K. had been scheduled to leave the union Friday. At least...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BC Week In Review | Mar 8, 2019
Company News

CHMP recommendations include Ondexxya, Waylivra

EMA's CHMP recommended a basket of approvals and label extensions on March 1, including Ondexxya andexanet alfa and Waylivra volanesorsen. The agency recommended conditional approval of Ondexxya from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) as the first...
BC Extra | Mar 1, 2019
Company News

CHMP recommendations include Ondexxya, Waylivra

EMA's CHMP recommended a basket of approvals and label extensions Friday, including Ondexxya andexanet alfa and Waylivra volanesorsen. The agency recommended conditional approval of Ondexxya from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) as the first approved antidote...
BC Extra | Jan 28, 2019
Company News

Management tracks: Ironwood reveals board for new companies

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) named Mark Currie as incoming president of its spinout Cyclerion Therapeutics Inc. Currie will also join Ironwood's board following the separation, which is on track to occur this half. He is...
Items per page:
1 - 10 of 270